For families living with sickle cell disease, access to the right medicine can mean the difference between another painful hospital visit and a more manageable life.
In Senegal, a new pharmaceutical initiative is bringing that reality into sharper focus as a locally manufactured version of an established sickle cell treatment enters the market.
Pharmaceutical company Teranga Pharma has begun producing DREPAF, a generic version of hydroxyurea used in the management of sickle cell disease.
The development has attracted attention not because Senegal has discovered a new cure, but because the country is attempting to manufacture an important treatment locally, potentially reducing some of the cost and supply challenges associated with imported medicines.
The project represents an investment of about 4 billion CFA francs, approximately US$7.1 million, in a pharmaceutical facility in Mbao, near Dakar.
For a disease that requires lifelong management, the significance of such an investment extends beyond the factory itself. It raises a larger question about whether African countries can increasingly produce the medicines their populations need.
A Treatment, Not a Cure
Hydroxyurea has been used for years as a disease-modifying treatment for sickle cell disease. It works in part by increasing levels of fetal haemoglobin, helping reduce the frequency and severity of some complications associated with the condition.
For many patients, that can translate into fewer painful crises, hospitalisations, blood transfusions and other serious complications.
But hydroxyurea is not a cure, and its benefits depend on consistent access, appropriate dosing, medical supervision and continued care. This distinction is important as Senegal’s DREPAF project attracts attention: the development is about improving access to an existing treatment rather than introducing a breakthrough medicine that eliminates sickle cell disease.
Africa’s Wider Sickle Cell Challenge
Sickle cell disease is particularly prevalent in sub-Saharan Africa, where thousands of children are born with the condition every year. In many communities, however, diagnosis can come late or not at all, while families may face difficulties accessing specialist care and essential medicines.
Countries across the continent have therefore been developing different approaches to the challenge.
Nigeria has expanded specialist centres, screening programmes, genetic counselling and treatment initiatives, while Nigerian pharmaceutical manufacturer Bond Chemical has also produced hydroxyurea locally. Ghana has strengthened newborn screening and specialist services, while countries including Uganda, Kenya, Angola and the Democratic Republic of Congo have participated in research and treatment programmes examining the use of hydroxyurea among children.
The American Society of Hematology’s Consortium on Newborn Screening in Africa (CONSA) has also supported screening initiatives in countries including Ghana, Kenya, Liberia, Nigeria, Tanzania, Uganda and Zambia.
Seen in that context, Senegal’s development is less an isolated breakthrough than another step in a growing African effort to confront sickle cell disease through diagnosis, treatment, research and local capacity.
The Cost of Access
For families managing sickle cell disease, however, medical evidence is only part of the story.
A treatment can be effective, but its impact is limited if patients cannot afford it or if supplies are unreliable.
DREPAF is being sold in Senegal at approximately 3,000 CFA francs for the 500mg formulation and 1,500 CFA francs for the 100mg paediatric version. The availability of a locally manufactured option could potentially ease some of the financial and supply pressures faced by patients, although the long-term impact will depend on production capacity, distribution and continued affordability. That is where local manufacturing becomes particularly important.
Producing medicines closer to the patients who need them could help reduce dependence on international supply chains and give African pharmaceutical companies greater control over production and distribution. But manufacturing locally does not automatically guarantee affordability or availability. Those benefits will depend on whether production can be sustained and medicines can consistently reach patients across different communities.
A Bigger African Ambition
Senegal’s pharmaceutical ambitions also extend beyond its own borders.
Teranga Pharma says it is working toward supplying countries including Burkina Faso, Guinea, Côte d’Ivoire, the Democratic Republic of Congo, Gabon and Cameroon. If those plans develop successfully, DREPAF could become part of a wider regional effort to strengthen access to locally produced sickle cell medicines.
The development also highlights an increasingly important conversation about pharmaceutical independence in Africa. For decades, many countries on the continent have depended heavily on imported medicines, leaving patients vulnerable to international supply disruptions, high prices and shortages.
Local production cannot solve all of those problems overnight. But each successful manufacturing initiative adds to the continent’s capacity to produce essential medicines closer to home.
Beyond One Medicine
The story of DREPAF is ultimately bigger than a single drug or pharmaceutical company.
For children born with sickle cell disease, survival and quality of life depend on a chain of care that begins with early diagnosis and continues through access to medicines, specialist treatment, blood transfusion services, infection prevention and regular medical monitoring.
Senegal’s decision to manufacture hydroxyurea locally adds another link to that chain.
It is not a cure, nor does it eliminate the many challenges surrounding sickle cell disease. But it represents an attempt to bring production closer to the people who need treatment and to strengthen Africa’s ability to respond to one of its longstanding health challenges.
If the medicine remains affordable, production can be sustained and distribution expands across borders, Senegal’s DREPAF project could become part of a much larger shift: an Africa that is not only treating its patients, but increasingly developing and manufacturing the medicines needed to treat them.
WARNING: If You Are Not 18+, Don’t Click The Link Below 👇🫣
Did you want to monetize your website, join MONETAG or ADSKEEPER and start earning
Please don’t forget to “Allow the notification” so you will be the first to get our gist when we publish it.
Drop your comment in the section below, and don’t forget to share the post.
Never Miss A Single News Or Gist, Kindly Join Us On WhatsApp Channel:
https://whatsapp.com/channel/0029Vad8g81Eawdsio6INn3B
Telegram Channel:
https://t.me/gistsmateNG